Superior Court Approves $2.5 Million Risperdal Verdict
Superior Court Approves $2.5 Million Risperdal Verdict
Introduction
On October 31, 2018, a unanimous three-judge panel in the Pennsylvania Superior Court upheld the $2.5 million Risperdal verdict awarded to an Alabama boy, who developed breasts due to the antipsychotic drug.
The case was the first among thousands of other product liability lawsuits filed against J&J. In August 2015, J&J appealed to overturn the verdict awarded to the plaintiff. The plaintiff was on Risperdal to treat his autism-related behavioral issues, and his parents claimed his abnormal breast growth was the result of the drug's side effect.
More than 7,000 Risperdal product liability lawsuits against J&J are filed in the Pennsylvania State Court. Two coordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775) and the other in Philadelphia (In Re: Risperdal Litigation, March 2010 Term, Case No. 100300296).
Comments
Latest News
Attorneys Seek Reconsideration of Talc MDL Daubert Ruling
Categories: General
Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…
Philips resolves DreamStation suits for $1.1B
Categories: Settlements
Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…
FDA OKs Generic OTC Naloxone Spray Approved by FDA
Categories: FDA Related
The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.
…